AIM AIM ImmunoTech Inc
Company Analysis
Latest News
🟢 AIM ImmunoTech is trading 5.5% up in pre-market — no clear catalyst identified
AIM ImmunoTech is trading at $0.17, up 5.47% in pre-market, with no clear company-specific catalyst identified for the October 23 gain. - The latest company...
🟢 AIM ImmunoTech is trading 5% up
AIM ImmunoTech is trading up 5.44% at $0.17 as of 10:44 a.m. ET on October 15, 2026, with no specific catalyst identified. - Price context shows a modest...
🔴 AIM ImmunoTech is trading 5% down today as weak markets pressure growth stocks
AIM ImmunoTech is trading at $0.16, down 5.06%, with broad market weakness appearing to weigh on growth stocks. - No clear company-specific announcement...
🟢 AIM ImmunoTech is trading 5% up
AIM ImmunoTech is trading at $0.19, up 5.28%; no announcement has explicitly linked the move to a catalyst. - An October 5 release highlighted recent media...
🟢 AIM ImmunoTech is trading 5.56% up in pre-market with no clear catalyst identified
AIM ImmunoTech is trading at $0.19, up 5.56%, with no clear catalyst identified. - No new company announcement dated October 5 was found. - The latest company...
🟢 AIM ImmunoTech is trading 5% up with no clear catalyst
AIM ImmunoTech is trading at $0.18, up 5.09%; available evidence does not establish a clear catalyst. - In an October 1 announcement, the company highlighted...
🔴 AIM ImmunoTech is trading 5% down today — cause unclear
AIM ImmunoTech is trading 5.26% down at $0.17, with no clear company-specific catalyst for the September 29 move. - The company’s press-release page lists...
🔴 AIM ImmunoTech is trading 5% down today with no clearly confirmed company-specific catalyst
AIM ImmunoTech is trading at $0.19, down 5.21%, with no clearly confirmed company-specific catalyst identified for September 25, 2026. - A recent...
🔴 AIM ImmunoTech is trading 5% down today as oil prices renew inflation and interest-rate concerns
AIM ImmunoTech is trading at $0.20, down 5.15%, likely amid broader risk-off trading as major U.S. indices fell and rising oil prices renewed inflation and...
🟢 AIM ImmunoTech is trading 5% up today in pre-market with no clearly identified company-specific catalyst
AIM ImmunoTech is trading +5.01% at $0.22, with no clearly identified company-specific catalyst for the September 22, 2026, pre-market move. - Recent company...
🔴 AIM ImmunoTech is trading 5% down today with no clear company-specific catalyst identified
AIM ImmunoTech is trading 5.06% down now at $0.21 after no clear company-specific catalyst was identified for September 18, 2026. - CEO Thomas Equels...
🔴 AIM ImmunoTech is trading 5% down in pre-market as no clear company-specific catalyst was identified
AIM ImmunoTech is trading 5.15% down at $0.21 after no clear company-specific catalyst was identified for September 18, 2026. - Recent disclosures include a...
AIM ImmunoTech Converts Approximately $400,000 of Debt into Common Stock
AIM ImmunoTech Inc. announced it has entered into exchange agreements to convert a portion of an outstanding promissory note into equity. The company settled...
🔴 AIM ImmunoTech is trading 5.5% down in pre-market amid broader risk-off conditions
AIM ImmunoTech is trading 5.5% down at $0.21 in pre-market as broader risk-off conditions, including weaker U.S. futures and rate concerns, appear to be the...
🔴 AIM ImmunoTech is trading 7.8% down in pre-market with no clear company-specific catalyst
AIM ImmunoTech is trading 7.8% down at $0.21 after no clear company-specific catalyst emerged overnight. - The latest official release, dated September 9,...
🔴 AIM ImmunoTech is trading 6.35% down today amid broader market weakness
AIM ImmunoTech is trading 6.35% down at $0.22, with no clear company-specific catalyst identified for the September 10, 2026 decline. - Latest highlighted...
🔴 AIM ImmunoTech is trading 5.45% down in pre-market with no clear company-specific catalyst
AIM ImmunoTech is trading at $0.22 (-5.45%) in pre-market with no clear company-specific catalyst for the September 10, 2026 decline. - On September 9, the...
AIM ImmunoTech Satisfies Promissory Note Through a $1.22M Debt-for-Equity Exchange
AIM ImmunoTech Inc. has fully satisfied a promissory note held by Streeterville Capital, LLC by converting the outstanding debt into common stock. The company...
AIM ImmunoTech Locks Down 15-Year European Patent for Long COVID Drug — But Can a $7 Million Company Turn Paper Protection Into Real Revenue?
Shares of AIM ImmunoTech jumped 10.8% to $0.26 after the micro-cap biotech announced it secured patent protection across Europe and the United Kingdom for its...
🟢 AIM ImmunoTech is trading 10.78% up today after European and UK patent protection through 2041
AIM ImmunoTech is trading 10.78% up now at $0.26 after securing European and United Kingdom patent protection for Ampligen’s Long COVID use through June...